{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:11:42Z","timestamp":1790626302687,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.yebeh.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T11:30:27Z","timestamp":1495711827000},"page":"73-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"PA","title":["Psychiatric side effects and antiepileptic drugs: Observations from prospective audits"],"prefix":"10.1016","volume":"71","author":[{"given":"Linda J.","family":"Stephen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbie","family":"Wishart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.04.003_bb0005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0140-6736(12)61455-X","article-title":"Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan","volume":"380","author":"Lin","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11910-002-0012-7","article-title":"Neuropsychiatric complications of epilepsy","volume":"2","author":"Kanner","year":"2002","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-244X-14-75","article-title":"The prevalence of psychosis in epilepsy; a systematic review and meta-analysis","volume":"14","author":"Clancy","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.yebeh.2016.03.020","article-title":"Anxiety disorders in people with epilepsy","volume":"59","author":"Brandt","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2014.11.023","article-title":"Risk factors for depression in community treated epilepsy: systematic review","volume":"43","author":"Lacey","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.seizure.2009.03.001","article-title":"Identifying depression in epilepsy in a busy clinical setting is enhanced with systematic screening","volume":"18","author":"Friedman","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.seizure.2013.11.012","article-title":"Utilization of care among drug resistant epilepsy patients with symptoms of anxiety and depression","volume":"23","author":"Hamilton","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2014.05.011","article-title":"The relationship of depression to antiepileptic drug adherence and quality of life in epilepsy","volume":"36","author":"Ettinger","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eplepsyres.2007.06.003","article-title":"Predictors of pharmacoresistant epilepsy","volume":"75","author":"Hitiris","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0050","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/01.wnl.0000343850.85763.9c","article-title":"A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy","volume":"72","author":"Kanner","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0055","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1212\/WNL.0b013e3181f25b16","article-title":"Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients","volume":"75","author":"Petrovski","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/ana.23601","article-title":"Epilepsy, suicidality, and psychiatric disorders: a bidirectional association","volume":"72","author":"Hesdorffer","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11599780-000000000-00000","article-title":"Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations","volume":"26","author":"Pieded","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2013.11.016","article-title":"Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?","volume":"31","author":"Brodie","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40263-015-0285-4","article-title":"Practical use of newer antiepileptic drugs as adjunctive therapy in focal epilepsy","volume":"29","author":"Brodie","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","article-title":"Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy","volume":"54","author":"Brodie","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0090","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: DSM V","author":"American Psychiatric Association","year":"2015"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0095","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1528-1157.2000.tb00282.x","article-title":"Topiramate in refractory epilepsy: a prospective observational study","volume":"41","author":"Stephen","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0100","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.yebeh.2004.07.009","article-title":"Levetiracetam for people with mental retardation and refractory epilepsy","volume":"5","author":"Kelly","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2004.02.006","article-title":"Levetiracetam in refractory epilepsy: a prospective observational study","volume":"14","author":"Mohanraj","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.yebeh.2010.01.016","article-title":"A prospective audit of adjunctive zonisamide in an everyday clinical setting","volume":"17","author":"Stephen","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0404.2011.01507.x","article-title":"Adjunctive pregabalin for uncontrolled partial-onset seizures: findings from a prospective audit","volume":"124","author":"Stephen","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0120","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.eplepsyres.2014.06.018","article-title":"Adjunctive lacosamide \u2014 5years' clinical experience","volume":"108","author":"Stephen","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.yebeh.2005.09.014","article-title":"The presence and clinical implications of depression in a community population of adults with epilepsy","volume":"8","author":"Mensah","year":"2006","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.yebeh.2011.05.026","article-title":"Depression screening for patients with epilepsy in a primary care setting using the Patient Health Questionnaire-2 and the Neurological Disorders Depression Inventory for Epilepsy","volume":"21","author":"Margrove","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0135","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1212\/01.WNL.0000138430.11829.61","article-title":"Depression and comorbidity in community-based patients with epilepsy or asthma","volume":"63","author":"Ettinger","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0140","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1111\/j.1528-1167.2007.01222.x","article-title":"Psychiatric comorbidity in epilepsy: a population-based analysis","volume":"48","author":"Tellez-Zenteno","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3988\/jcn.2014.10.3.175","article-title":"Depression and anxiety in people with epilepsy","volume":"10","author":"Kwon","year":"2014","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0150","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1528-1167.2010.02927.x","article-title":"Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey","volume":"52","author":"Ottman","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0155","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1212\/WNL.0b013e31827b1ae0","article-title":"Depression in epilepsy. A systematic review and meta-analysis","volume":"80","author":"Fiest","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0160","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/epi.13302","article-title":"What factors contribute to the risk of depression in epilepsy? \u2013 Tasmanian Epilepsy Register Mood Study (TERMS)","volume":"57","author":"Lacey","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/jnnp.61.1.82","article-title":"Psychiatric disorders in candidates for surgery for epilepsy","volume":"61","author":"Manchanda","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0404.2004.00324.x","article-title":"The psychiatric comorbidity of epilepsy","volume":"110","author":"Gaitatzis","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yebeh.2015.09.024","article-title":"Psychiatric disorders among 165 patients with juvenile myoclonic epilepsy in India and association with clinical and sociodemographic variables","volume":"53","author":"Somayajula","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0180","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14737175.2016.1179113","article-title":"Modern management of juvenile myoclonic epilepsy","volume":"16","author":"Brodie","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0185","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1528-1167.2011.03136.x","article-title":"The prevalence of atypical presentations and comorbidities of benign childhood epilepsy with centrotemporal spikes","volume":"52","author":"Tovia","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0190","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1528-1167.2005.43604.x","article-title":"Depression and anxiety disorders in pediatric epilepsy","volume":"46","author":"Caplan","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2007.01482.x","article-title":"Frontal cognitive dysfunction in juvenile myoclonic epilepsy","volume":"49","author":"Piazzini","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0200","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181b9c86f","article-title":"Juvenile myoclonic epilepsy 25years after seizure onset: a population-based study","volume":"73","author":"Camfield","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0205","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2006.08.008","article-title":"Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy","volume":"10","author":"Weintraub","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1525-5050(03)00005-2","article-title":"A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials","volume":"4","author":"Cramer","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.seizure.2015.07.012","article-title":"Gender differences in depression, but not in anxiety in people with epilepsy","volume":"32","author":"Gaus","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0225","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.yebeh.2003.07.008","article-title":"Aggressive behaviour of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases","volume":"4","author":"Dinkelacker","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0230","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/jnnp.74.11.1485","article-title":"Psychopathology in people with intellectual disability: an investigation of potential explanatory variables","volume":"74","author":"Espie","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0235","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1059-1311(02)00265-0","article-title":"Perspectives on epilepsy in people with intellectual disabilities: comparison of family carer, staff carer and clinician score profiles on the Glasgow Epilepsy Outcome Scale (GEOS)","volume":"12","author":"Espie","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0240","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.yebeh.2007.04.002","article-title":"Interactions between seizure frequency, psychopathology, and severity of intellectual disability in a population with epilepsy and a learning disability","volume":"11","author":"Ring","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0245","first-page":"224","article-title":"Comparative survey of comorbidities in people with learning disability with or without epilepsy","volume":"32","author":"Pawar","year":"2008","journal-title":"BJPsych Bull"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0250","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11920-005-0062-z","article-title":"Diagnosis and treatment of depression in patients with mental retardation","volume":"7","author":"Janowsky","year":"2005","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.yebeh.2017.04.003_bb0255","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:JADD.0000005999.27178.55","article-title":"Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation","volume":"33","author":"Esbensen","year":"2003","journal-title":"J Autism Dev Disord"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016306783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016306783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:10:00Z","timestamp":1719223800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016306783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":51,"alternative-id":["S1525505016306783"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.04.003","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychiatric side effects and antiepileptic drugs: Observations from prospective audits","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}